Akros SCHK HK-U.S. Biotech Index

FDA decision (PDUFA date) for the once-daily HIV single-tablet regimen, bictegravir/lenacapavir (BIC/LEN), is scheduled.

Gilead Q2 2026 earnings release expected.

Q2 2026 earnings release and conference call scheduled. High investor focus on the sales momentum of GLP-1 drugs is expected.

Q2 2026 earnings release and conference call scheduled for 2026-08-04; estimated >10% price impact based on historical volatility scheduled.

Merck's Q2 2026 earnings release and conference call are scheduled. Analysts forecast EPS of $2.15 and revenue of $16.3 billion, forecasted. High importance is estimated as quarterly results for a mega-cap pharmaceutical company typically drive ≥10% price volatility, scheduled.

Pfizer's second-quarter 2026 earnings and revenue results are scheduled to be released before the market opens on August 4, 2026. High impact (>=10%) is estimated as a major quarterly catalyst, scheduled.

AbbVie is scheduled to announce its second-quarter 2026 financial results before the market opens, as announced on June 26, 2026. A Low impact is estimated as the announcement of the date itself typically has minimal immediate price effect, scheduled.

Bristol-Myers Squibb will announce results for the second quarter of 2026 on Thursday, July 30, 2026; Medium importance estimated due to typical earnings volatility, scheduled.

Abbott is scheduled to report its Q2 2026 financial results before the market opens on July 16, 2026. Analysts forecast EPS of $1.28 on revenue of $12.52 billion. The company's guidance for the quarter is an adjusted EPS of $1.25 to $1.31. Medium importance is estimated as earnings for large-cap stocks often cause 5-10% price movement, and this event is scheduled.

Johnson & Johnson is scheduled to report its Q2 2026 financial results before the market opens on July 15, 2026. Analysts forecast EPS around $2.86 on revenues of approximately $25.06 billion. High importance is assigned as major earnings surprises can lead to price impacts exceeding 10%. This is scheduled.

The U.S. FDA approved KEYTRUDA and KEYTRUDA QLEX, each combined with Padcev, as a perioperative treatment for adults with muscle-invasive bladder cancer (MIBC), expanding its use regardless of cisplatin eligibility. High importance is estimated due to the significant expansion of the addressable market for Merck's primary revenue driver, likely resulting in ≥10% long-term valuation impact, expected.

Pfizer and Astellas received U.S. FDA approval for PADCEV in combination with Keytruda for muscle-invasive bladder cancer on July 10, 2026. High impact (>=10%) is estimated due to the first-in-class status.

The European Commission approved TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma.